CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval

 
• By Alaric DeArment

The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.

FDA Approved
CTI won its first FDA approval, with the agency giving its nod to the myelofibrosis drug Vonjo • Source: Shutterstock

More from New Products

More from Scrip